Leerink bullish on BioMarin acquiring Inozyme Pharma, sees potential for further growth

From Yahoo Finance: 2025-05-17 13:30:00

BioMarin is set to acquire Inozyme Pharma for $270M, adding INZ-701 to its ERT portfolio with a potential peak value of $400M-$600M. Analysts at Leerink see this as a strategic move for BioMarin, expecting more business development deals under James Sabry’s leadership as Chief Business Officer.

Leerink notes BioMarin’s acquisition of Inozyme Pharma as a positive step, aligning with their strategy for 2025. The $270M all-cash transaction for $4.00/share marks the first business development deal of the year. With a focus on expanding their ERT portfolio, BioMarin anticipates further growth through potential BD transactions. Leerink reaffirms an Outperform rating on the company’s shares.

Read more: Leerink bullish on BioMarin following Inozyme deal, expects additional BD